Glycogen phosphorylase inhibition as a therapeutic target: A review of the recent patent literature

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 4, 2006, Pages 459-466

  Baker, David J ^a   Greenhaff, Paul L ^b   Timmons, James A ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c Center for Molecular Biology   (Sweden)

Author keywords

Glycogen phophorylase; Non insulin dependent diabetes mellitus (NIDDM); Obesity; Type 2 diabetes

Indexed keywords

2 AMINOBENZOIC ACID 2 (5 CHLORO 1 H INDOL 2 YLCARBONYL)HYDRAZIDE; 2 CHLORO N [1 (2 METHYLSULFONYLETHYL) 2 OXO 1,2,3,4 TETRAHYDRO 1,5 NAPHTHYRIDIN 3 YL] 6H THIENO[2,3 B]PYRROLE 5 CARBOXAMIDE; 2 CHLORO N [1 (5 HYDROXYMETHYL 2 OXO OXAZOLIDIN 3 YL) 2,3 DIHYDRO 1H INDEN 2 YL] 6H THIENO[2,3 B]PYRROLE 5 CARBOXAMIDE; 5 CHLORO N [3 (DIMETHYLAMINO) 2 HYDROXY 3 OXO 1 (PHENYLMETHYL)PROPYL] 1H INDOLE 2 CARBOXAMIDE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; AZITHROMYCIN; BAY R 3401; CHOLESTEROL; CP 316819; CP 320 626; CP 91149; ENZYME INHIBITOR; GLUCOSE; GLUCOSE 6 PHOSPHATE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; GLYCOGEN PHOSPHORYLASE INHIBITOR; INOSINE PHOSPHATE; INSULIN; LIVER ENZYME; METHYL 2 (5 CHLORO 1H INDOL 2 YLCARBONYLAMINO) INDANE 1 CARBOXYLATE; N BENZOYL N' (3 CARBOXYPHENYL)UREA DERIVATIVE; N BENZOYL N' (4 CARBOXYPHENYL)UREA DERIVATIVE; N NAPHTHOYL N' (CARBAMOYLPHENYL)UREA DERIVATIVE; PSN 357; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BRAIN; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; GENE TARGETING; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; REVIEW; SKELETAL MUSCLE; TISSUE DISTRIBUTION; VALIDATION PROCESS;

EID: 33645794959     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.4.459     Document Type: Review

References (68)

1. CHASIOTIS D, SAHLIN K, HULTMAN E: Regulation of glycogenolysis in human muscle at rest and during exercise. J. Appl. Physiol. (1982) 53:708-715.
2. CHASIOTIS D, SAHLIN K, HULTMAN E: Regulation of glycogenolysis in human muscle in response to epinephrine infusion. J. Appl. Physiol. (1983) 54:45-50.
3. CHASIOTIS D: Effects of adrenaline infusion on cAMP and glycogen phosphorylase in fast-twitch and slow-twitch rat muscles. Acta. Physiol. Scand. (1985) 125:537-540.
4. CHASIOTIS D: Role of cyclic AMP and inorganic phosphate in the regulation of muscle glycogenolysis during exercise. Med. Sci. Sports Exerc. (1988) 20:545-550.
5. REN JM, CHASIOTIS D, BERGSTROM M, HULTMAN E: Skeletal muscle glucolysis, glycogenolysis and glycogen phosphorylase during electrical stimulation in man. Acta Physiol. Scand. (1988) 133:101-107.
6. REN JM, HULTMAN E: Phosphorylase activity in needle biopsy samples - factors influencing transformation. Acta Physiol. Scand. (1988) 133:109-114.
7. REN JM, HULTMAN E: Regulation of phosphorylase a activity in human skeletal muscle. J. Appl. Physiol. (1990) 69:919-923.
8. TAPPY L: Regulation of hepatic glucose production in healthy subjects and patients with non-insulin-dependent diabetes mellitus. Diabetes Metab. (1995) 21:233-240.
9. TAPPY L, JEQUIER E, SCHNEITER P: Autoregulation of glucose production. News Physiol. Sci. (2000) 15:198-202.
10. 2+ ATPase in skeletal muscle. J. Theor. Biol. (2006) 238:257-268.
11. NEWGARD CB, HWANG PK, FLETTERICK RJ: The family of glycogen phosphorylases: structure and function. Crit. Rev. Biochem. Mol. Biol (1989) 24:69-99.
12. RATH VL, AMMIRATI M, DANLEY DE et al.: Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem. Biol. (2000) 7:677-682.
13. ERCAN-FANG N, NUTTALL FQ: The effect of caffeine and caffeine analogs on rat liver phosphorylase a activity. J. Pharmacol. Exp. Ther. (1997) 280:1312-1318.
14. ERCAN-FANG NG, NUTTALL FQ, GANNON MC: Uric acid inhibits liver phosphorylase a activity under simulated in vivo conditions. Am. J. Physiol. Endocrinol. Metab. (2001) 280:E248-E253.
15. KASVINSKY PJ, SHECHOSKY S, FLETTERICK RJ: Synergistic regulation of phosphorylase a by glucose and caffeine. J. Biol. Chem. (1978) 253:9102-9106.
16. KASVINSKY PJ, MADSEN NB, SYGUSCH J, FLETTERICK RJ: The regulation of glycogen phosphorylase α by nucleotide derivatives. Kinetic and X-ray crystallographic studies. J. Biol. Chem. (1978) 253:3343-3351.
17. OIKONOMAKOS NG, SCHNIER JB, ZOGRAPHOS SE et al.: Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem. (2000) 275:34566-34573.
18. EKSTROM JL, PAULY TA, CARTY MD et al.: Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase. Chem. Biol. (2002) 9:915-924.
19. KOSMOPOULOU MN, LEONIDAS DD, CHRYSINA ED et al.: Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to pCDK2-cyclin A complex. Eur. J. Biochem. (2004) 271:2280-2290.
20. KOSMOPOULOU MN, LEONIDAS DD, CHRYSINA ED, EISENBRAND G, OIKONOMAKOS NG: Indirubin-3′-aminooxy-acetate inhibits glycogen phosphorylase by binding at the inhibitor and the allosteric site. Broad specificities of the two sites. Letts. Drug Des. Discov. (2005):377-390.
21. OIKONOMAKOS NG, SKAMNAKI VT, TSITSANOU KE, GAVALAS NG, JOHNSON LN: A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure Folding Des. (2000) 8:575-584.
22. BJORNHOLM M, ZIERATH JR: Insulin signal transduction in human skeletal muscle: identifying the defects in Type 2 diabetes. Biochem. Soc. Trans. (2005) 33:354-357.
23. KROOK A, WALLBERG-HENRIKSSON H, ZIERATH JR: Sending the signal: molecular mechanisms regulating glucose uptake. Med. Sci. Sports Exerc. (2004) 36:1212-1217.
24. CONSOLI A: Role of liver in pathophysiology of NIDDM. Diabetes Care (1992) 15:430-441.
25. DEFRONZO RA: Pathogenesis of Type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia (1992) 35:389-397.
26. DEFRONZO RA, BONADONNA RC, FERRANNINI E: Pathogenesis of NIDDM. A balanced overview. Diabetes Care (1992) 15:318-368.
27. EDELMAN SV: Type 2 diabetes mellitus. Adv. Intern. Med. (1998) 43:449-500.
28. SHAW RJ, LAMIA K A, VASQUEZ D et al.: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 310:1642-1646.
29. BARRETT EJ, LIU Z: Hepatic glucose metabolism and insulin resistance in NIDDM and obesity. Baillieres Clin. Endocrinol. Metab. (1993) 7:875-901.
30. SHIOTA M, JACKSON PA, BISCHOFF H et al.: Inhibition of glycogenolysis enhances gluconeogenic precursor uptake by the liver of conscious dogs. Am. J. Physiol. (1997) 273:E868-E879.
31. ERCAN-FANG N, TAYLOR MR, TREADWAY JL et al.: Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitors. Am. J. Physiol. Endocrinol. Metab. (2005) 289:E366-E372.
32. MARTIN WH, HOOVER DJ, ARMENTO SJ et al.: Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc. Natl. Acad. Sci. USA (1998) 95:1776-1781.
33. OGAWA AK, WILLOUGHBY CA, BERGERON R et al.: Glucose-lowering in a db/db mouse model by dihydropyridine diacid glycogen phosphorylase inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:3405-3408.
34. MARTIN JL, VELURAJA K, ROSS K et al.: Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes. Biochemistry (1991) 30:10101-10116.
35. OIKONOMAKOS NG, KONTOU M, ZOGRAPHOS SE et al.: The design of potential antidiabetic drugs: experimental investigation of a number of β-D-glucose analogue inhibitors of glycogen phosphorylase. Eur. J. Drug Metab. Pharmacokinet. (1994) 19:185-192.
36. SOMSAK L, NAGYA V, HADADY Z, DOCSA T, GERGELY P: Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments. Curr. Pharm. Des. (2003) 9:1177-89.
37. SPRANG SR, GOLDSMITH EJ, FLETTERICK RJ, WITHERS SG, MADSEN NB: Catalytic site of glycogen phosphorylase: structure of the T state and specificity for α-D-glucose. Biochemistry (1982) 21:5364-5371.
38. WATSON KA, MITCHELL EP, JOHNSON LN et al.: Design of inhibitors of glycogen phosphorylase: a study of α-and β-C-glucosides and 1-thio-β-D-glucose compounds. Biochemistry (1994) 33:5745-5758.
39. WATSON KA, MITCHELL EP, JOHNSON LN et al.: Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection. Acta Crystallogr. D. Biol. Crystallogr. (1995) 51:458-472.
40. CHRYSINA ED, OIKONOMAKOS NG, ZOGRAPHOS SE et al.: Crystallographic studies on α- and β-D-glucopyranosyl formamide analogues, inhibitors of glycogen phosphorylase. Biocatal. Biotransformation (2003) 21:233-242.
41. CHRYSINA ED, KOSMOPOULOU MN, TIRAIDIS C et al.: Kinetic and crystallographic studies on 2-(β-D-glucopyranosyl)-5-methyl-1,3,4-oxadiazole, -benzothiazole, and -benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site. Protein Sci. (2005) 14:873-888.
42. GYORGYDEAK Z, HADADY Z, FELFOLDI N et al.: Synthesis of N-(β-D-glucopyranosyl)- and N-(2-acetamido-2-deoxy-β-D-glucopyranosyl) amides as inhibitors of glycogen phosphorylase. Bioorg. Med. Chem. (2004) 12:4861-4870.
43. OIKONOMAKOS NG: Glycogen phosphorylase as a molecular target for Type 2 diabetes therapy. Curr. Protein Peptide Sci. (2002) 3:561-586.
44. OIKONOMAKOS NG, KOSMOPOULOU M, ZOGRAPHOS SE et al.: Binding of N-acetyl-N′-β-D-glucopyranosyl urea and N-benzoyl-N′-β-D-glucopyranosyl urea to glycogen phosphorylase b - kinetic and crystallographic studies. Eur. J. Biochem. (2002) 269:1684-1696.
45. SOMSAK L, NAGY V, HADADY Z et al.: Recent developments in the synthesis and evaluation of glucose analog inhibitors of glycogen phosphorylase as potential antidiabetic agents. (2005) 2:253-272.
46. WATSON KA, CHRYSINA ED, TSITSANOU KE et al.: Kinetic and crystallographic studies of glucopyranose spirohydantoin and glucopyranosylamine analogs inhibitors of glycogen phosphorylase. Proteins Struct. Function Bioinformat. (2005) 61:966-983.
47. KRISTIANSEN M, ANDERSEN B, IVERSEN LF, WESTERGAARD N: Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site. J. Med. Chem. (2004) 47:3537-3545.
48. LU Z, BOHN J, BERGERON R et al.: A new class of glycogen phosphorylase inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:4125-4128.
49. ZOGRAPHOS SE, OIKONOMAKOS NG, TSITSANOU KE et al.: The structure of glycogen phosphorylase b with an alkyldihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor. Structure (1997) 5:1413-1425.
50. ROSAUER KG, OGAWA AK, WILLOUGHBY CA et al.: Novel 3,4-dihydroquinolin-2(1H)-one inhibitors of human glycogen phosphorylase a. Bioorg. Med. Chem. Lett. (2003) 13:4385-4388.
51. WRIGHT SW, RATH VL, GENEREUX PE et al.: 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization. Bioorg. Med. Chem. Lett. (2005) 15:459-465.
52. KLABUNDE T, WENDT KU, KADEREIT D et al.: Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes. J. Med. Chem. (2005) 48:6178-6193.
53. ANDERSEN B, WESTERGAARD N: The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors. Biochem. J. (2002) 367:443-450.
54. HOOVER DJ, LEFKOWITZ-SNOW S, BURGESS-HENRY JL et al.: Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. J. Med. Chem. (1998) 41:2934-2938.
55. TREADWAY JL, MENDYS P, HOOVER DJ: Glycogen phosphorylase inhibitors for treatment of Type 2 diabetes mellitus. Expert Opin. Investig. Drugs (2001) 10:439-454.
56. SYSOLIATINA NA, SAPOZHKOV AV: [Role of glycogenolysis inhibition in the etiology of arrhythmias in coronary disease]. Vopr. Med. Khim. (1982) 28:56-59.
57. WEISS RG, DE ALBUQUERQUE CP, VANDEGAER K, CHACKO VP, GERSTENBLITH G: Attenuated glycogenolysis reduces glycolytic catabolite accumulation during ischemia in preconditioned rat hearts. Circ. Res. (1996) 79:435-446.
58. TRACEY WR, TREADWAY JL, MAGEE WP et al.: Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor. Am. J. Physiol. Heart Circ. Physiol. (2004) 286:H1177-H1184.
59. LINZ W, ALBUS U, CRAUSE P et al.: Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 inhibitor cariporide (HOE 642). Clin. Exp. Hypertens. (1998) 20:733-749.
60. TAKAHASHI S, SATOMI A, YANO K et al.: Estimation of glycogen levels in human colorectal cancer tissue: relationship with cell cycle and tumor outgrowth. J. Gastroenterol. (1999) 34:474-480.
61. YANG K, OHOSHIMA S, SHIMIZU Y, MORIGUCHI T, KATAYAMA H: Evaluation of glycogen level in human lung carcinoma tissues by an infrared spectroscopic method. Cancer Lett. (1996) 110:29-34.
62. ROUSSET M, DUSSAULX E, CHEVALIER G, ZWEIBAUM A: Growth-related glycogen levels of human intestine carcinoma cell lines grown in vitro and in vivo in nude mice. J. Natl. Cancer Inst. (1980) 65:885-889.
63. BAKER DJ, TIMMONS JA, GREENHAFF PL: Glycogen phosphorylase inhibition in Type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes (2005) 54:2453-2459.
64. BRADLEY C: Importance of differentiating health status from quality of life. Lancet (2001) 357:7-8.
65. FLEG JL, MORRELL CH, BOS AG et al.: Accelerated longitudinal decline of aerobic capacity in healthy older adults. Circulation (2005) 112:674-682.
66. MANCINI D, BENAMINOVITZ A, CORDISCO ME, KARMALLY W, WEINBERG A: Slowed glycogen utilization enhances exercise endurance in patients with heart failure. J. Am. Coll. Cardiol. (1999) 34:1807-1812.
67. TIMMONS JA, POUCHER SM, CONSTANTIN-TEODOSIU D, MACDONALD IA, GREENHAFF PL: Metabolic responses from rest to steady state determine contractile function in ischemic skeletal muscle. Am. J. Physiol. (1997) 273:E233-E238.
68. VAN LOON LJ, GOODPASTER BH: Increased intramuscular lipid storage in the insulin-resistant and endurance-trained state. Pflugers Arch. (2005) 451(5):606-616.